Nefecon Included in the Reimbursement Drug List of “Beijing Puhui Health Insurance Program” as a First-in-Disease Therapy for IgA Nephropathy
SHANGHAI, May 11, 2023 /PRNewswire/ — An imported version of Nefecon (budesonide) delayed release capsule has been added to the 2023 New Reimbursement Drug List of Specialized Medicines of the “Beijing Puhui Health Insurance Program.” Nefecon is a first-in-disease treatment for adults with primary immunoglobulin A nephropathy (IgAN). Nefecon has been approved by the United States Food … Read more